NeuroPace Receives FDA Approval for AI-Powered ECoG Assistant to Enhance Epilepsy Care
核心洞察
NeuroPace announced FDA approval of ECoG Assistant (搜索), the first AI-driven clinician tool in its planned suite of artificial intelligence applications for epilepsy (搜索) management.
The AI model was trained on 124,450 epileptologist-labeled intracranial EEG records, enabling faster identification of ECoGs of Interest and more efficient clinical decision-making.
The company plans to debut ECoG Assistant (搜索) at the American Society for Stereotactic and Functional Neurosurgery Annual Meeting on May 30th, 2026.
NeuroPace, Inc. (Nasdaq: NPCE) has received FDA approval for ECoG Assistant (搜索), marking a significant advancement in AI-driven epilepsy (搜索) care. The approval represents the first in a planned suite of artificial intelligence tools designed to leverage the world's only long-term intracranial EEG dataset for enhanced epilepsy monitoring and management.
AI-Powered Clinical Decision Support
ECoG Assistant (搜索) is designed to support clinical decision-making through deeper data insights and more efficient ECoG review. The AI model was developed using 124,450 epileptologist-labeled intracranial EEG (iEEG) long-episode records, enabling it to identify ECoGs of Interest from this extensive dataset.
The tool provides clinicians with a comprehensive single-view interface to review ECoGs of Interest spanning months through the ECoG Assistant (搜索) Trends Report. Additionally, physicians can explore timing patterns and potential triggers using the integrated Circadian Pattern Chart functionality.
"ECoG Assistant (搜索) represents an important advancement in how clinicians interact with iEEG data and the RNS System (搜索)," said Dr. Martha Morrell, Chief Medical Officer at NeuroPace. "By harnessing AI trained on a subset of the largest intracranial EEG dataset in the world, we are enabling faster access to insights that can support more efficient care and informed treatment decisions."
Strategic AI Platform Development
The approval underscores NeuroPace's broader AI platform strategy, which builds upon proprietary patient-level brain data captured through the RNS System (搜索). Joel Becker, Chief Executive Officer of NeuroPace, emphasized the significance of this data advantage in translating into practical clinical tools.
"This approval underscores how NeuroPace's data advantage is translating into practical tools for clinicians today," Becker stated. "AI-driven insights offer the unique potential to improve the efficiency of epilepsy (搜索) care now while building a platform that can unlock new opportunities over time to further personalize therapy and improve outcomes."
Clinical Debut and Future Infrastructure
NeuroPace plans to officially debut ECoG Assistant (搜索) at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Annual Meeting on May 30th, 2026, where clinicians will experience the new technology firsthand.
The company has also submitted its next-generation Patient Data Management System (PDMS) for FDA review. This cloud-based platform is designed to modernize the underlying software infrastructure supporting the RNS System (搜索). If approved, the platform is expected to improve reliability and scalability for clinicians and patients while providing a more flexible foundation to support AI-enabled capabilities, including additional workflow tools beyond ECoG Assistant (搜索).
NeuroPace currently expects Next-Generation PDMS approval in the second quarter of 2026.
RNS System Foundation
The ECoG Assistant (搜索) builds upon NeuroPace's RNS System (搜索), which is described as the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform is designed to drive a better standard of care for patients living with drug-resistant epilepsy (搜索) and has potential applications for other brain disorders.